The Drummond Report is attracting significant attention with its somewhat dire outlook for the Ontario economy. The report includes a notable warning about the costs of the proposed Canada – EU Trade Agreement, particularly the increased costs arising from patent reforms being promoted by large pharmaceutical companies: The outcome of […]
Post Tagged with: "pharma"
Report Says Canada – EU Trade Deal Could Cost Ontario $1.2 Billion Per Year From Higher Pharma Costs
Canadian Pharma: High Prices, Low Research & Development
The Globe’s Jeffrey Simpson has an excellent column on the state of big pharma in Canada, noting that Canadians pay high prices for pharmaceuticals but that big pharma has not met its commitment to devote 10 percent of sales to research and development. Prices would increase further with potential legal […]
Beware Big Pharma Ghostwriters
Dr. Marc-André Gagnon, an assistant professor with the School of Public Policy and Administration at Carleton University and Dr. Sergio Sismondo, professor of Philosophy and Sociology at Queen’s University, write an op-ed about the growing problem of big pharmaceutical companies ghost writing opinion pieces in support of their drugs.
CETA Could Cost Drug Plans Billions
The Globe covers a new report that projects that the proposed Canada – European Union Trade Agreement could add nearly $3 billion in additional costs to provincial drug plans.
Recent Posts
Debating the Online Harms Act: Insights from Two Recent Panels on Bill C-63 
The Law Bytes Podcast, Episode 199: Boris Bytensky on the Criminal Code Reforms in the Online Harms Act 
AI Spending is Not an AI Strategy: Why the Government’s Artificial Intelligence Plan Avoids the Hard Governance Questions 
The Law Bytes Podcast, Episode 198: Richard Moon on the Return of the Section 13 Hate Speech Provision in the Online Harms Act 
Tweets Are Not Enough: Why Combatting Relentless Antisemitism in Canada Requires Real Leadership and Action
